COVID-19 Vaccine

ApprovedVaccine

Moderna

COVID-19 Vaccine is one of 253 biologic programs targeting Liver Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

252

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Rheumatic DiseaseActive, not recruiting

Lung CancerActive, not recruiting

Long COVID-19Active, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

HypertensionActive, not recruiting

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Liver TransplantPreclinical

Active, not recruiting

Rheumatic DiseasePhase 2/Phase 3

Active, not recruiting

Lung CancerPreclinical

Active, not recruiting

Long COVID-19Preclinical

Active, not recruiting

Inflammatory Bowel DiseasePreclinical

Active, not recruiting

HypertensionApproved

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

InfluenzaPhase 1/Phase 2

Active, not recruiting

Sickle Cell DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

COVID-19 Vaccine

Moderna

Approved

27 2

Achromycin V

WWyeth-Lederle Vaccines

Glucocorticoid

1 4

Calcium

Olokizumab

1 6

Conventional

PPopulation Health Research Institute

Preclinical

1 7

Blood Taken

HHospices Civils de Lyon

Preclinical

1 8

Exoflo

DDirect Biologics, LLC

Preclinical

3 9

Tpa

UUniversity of Florida

Preclinical

1 10

Hydroxychloroquine Pill

UUniversity of Calgary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Pregnancy

NCT04705116

Phase 1Recruiting

Influenza

NCT06355232

Phase 3Recruiting

COVID-19

NCT05415267

Q4 2027

Phase 2Active, not recruiting

Blood Cancer

NCT04977024

Q4 2030

Recruiting

COVID-19

NCT04706390

Clinical

Trials by Indication[1]

COVID-1927 trials

Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination

Completed· Moderna logo

Moderna··NCT04941144·8,538 enrolled

Plant Stanol Esters and COVID-19 Vaccination Response

Terminated·MMaastricht University Medical Center·N/A·NCT04844346·48 enrolled

Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine

Completed·UUniversità degli Studi dell'Insubria··NCT05083065·369 enrolled

Show 24 more trials

Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients

Completed·—··NCT04922944·167 enrolled

Immunogenicity of COVID-19 Vaccination in PLWH

Unknown status·CCIHR Canadian HIV Trials Network··NCT04894448·500 enrolled

COVID-19 Vaccine Effectiveness in Albanian Health Workers

Unknown status·—··NCT04811391·1,500 enrolled

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

Completed· BioNTech logo

BioNTech·Phase 1/2·NCT06683352·1,353 enrolled

Host Immune Response to Novel RNA COVID-19 Vaccination

Completed·TThe University of Texas Health Science Center at San Antonio··NCT04784689·50 enrolled

The Impact of Vaccination on Severity of Illness in COVID-19

Completed·CCorewell Health East··NCT04912700·11,834 enrolled

Oral Side Effects of COVID-19 Vaccine

Unknown status·MMasaryk University··NCT04706156·1,540 enrolled

COVID-19 Vaccine Response in Chronic Respiratory Conditions

Unknown status·NNational Jewish Health··NCT05313087·600 enrolled

Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

Completed·SSeoul National University Hospital··NCT04910295·112 enrolled

Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults

Unknown status·—·Phase 4·NCT05012800·300 enrolled

Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium

Unknown status·UUniversiteit Antwerpen··NCT05618548·110 enrolled

Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms

Withdrawn· Takeda logo

Takeda··NCT04892888

Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19)

Active, not recruiting·QQueen Mary University of London·Phase 1·NCT04889274·98 enrolled

Exercise and COVID-19 Viral T-cell Immunity

Active, not recruiting·UUniversity of Arizona·N/A·NCT05019456·26 enrolled

To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment

Unknown status·UUniversity of Kansas Medical Center··NCT04821570·500 enrolled

Immunosuppression and COVID-19 Boosters

Recruiting·KKirby Institute·Phase 3·NCT05415267·320 enrolled

Covid-19 Vaccine Cohort in Specific Populations

Unknown status·AANRS, Emerging Infectious Diseases··NCT04824651·6,920 enrolled

Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination

Recruiting·UUniversity of Bergen··NCT04706390·2,500 enrolled

Expectations About the COVID-19 Vaccines

Completed·UUniversity of Aarhus··NCT04928911·1,176 enrolled

Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)

Unknown status·AAlberto Peano··NCT05471635·205 enrolled

Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.

Unknown status·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 4·NCT05157178·1,264 enrolled

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Unknown status·NNational Vaccine and Serum Institute, China·Phase 2·NCT05033847·1,800 enrolled

Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine

Unknown status·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 4·NCT05142488·662 enrolled

Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation

Withdrawn·TThe First Affiliated Hospital of Soochow University··NCT05587881

Influenza8 trials

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

Active, not recruiting· Pfizer logo

Pfizer··NCT05160636·999 enrolled

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.

Withdrawn· Pfizer logo

Pfizer··NCT06163677

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

Completed· Moderna logo

Moderna·Phase 1/2·NCT05827926·1,758 enrolled

Show 5 more trials

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Completed· Moderna logo

Moderna·Phase 2·NCT06864143·1,320 enrolled

Covid-19 and Influenza Oral Vaccine Study

Recruiting·VVaxine Pty Ltd·Phase 1·NCT06355232·100 enrolled

Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

Completed·UUniversity of Wisconsin, Madison··NCT05584735·46 enrolled

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Completed· BioNTech logo

BioNTech·Phase 3·NCT06178991·8,795 enrolled

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Completed· Moderna logo

Moderna·Phase 3·NCT06097273·8,061 enrolled

Immunogenicity2 trials

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05453487·360 enrolled

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05480436·1,200 enrolled

Rheumatic Disease2 trials

COVID-19 Vaccination in Patients With Rheumatic Diseases

Unknown status·SSociedad Argentina de Reumatologia··NCT04845997·3,000 enrolled

COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases

Unknown status·PPaul R Fortin·Phase 2/3·NCT05236491·287 enrolled

Inflammatory Bowel Disease2 trials

Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases

Unknown status·RRabin Medical Center··NCT05067959·284 enrolled

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

Unknown status·GGI Alliance··NCT05014555·400 enrolled

11 more indications

Pregnancy2 trials

COVID-19 Vaccines International Pregnancy Exposure Registry

Recruiting·PPregistry··NCT04705116·6,000 enrolled

COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes

Completed·TThomas Jefferson University··NCT04659759·105 enrolled

Hypertension2 trials

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05104333·1,440 enrolled

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05104437·1,440 enrolled

Liver Transplant1 trial

Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation

Unknown status·—··NCT05051605·50 enrolled

Vaccine1 trial

Vaccine Observation to Include All Communities for Equitable Science

Terminated·PPersephone Biosciences··NCT04770649·15 enrolled

Immune Response1 trial

Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women

Unknown status·SSwiss Federal Institute of Technology·N/A·NCT06116669·180 enrolled

Sickle Cell Disease1 trial

COVID-19 Vaccine Response in Sickle Cell Disease

Completed·AASH Research Collaborative··NCT05139992·59 enrolled

Long COVID-191 trial

COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients

Unknown status·IIndonesia University··NCT05587868·250 enrolled

Vaccine Response1 trial

Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

Completed·NNicole Stoffel·N/A·NCT05919472·180 enrolled

Lung Cancer1 trial

Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients

Completed·FFundación GECP··NCT05009030·794 enrolled

Blood Cancer1 trial

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Active, not recruiting·GGeoVax, Inc.·Phase 2·NCT04977024·63 enrolled

Immunity1 trial

Gestational Immunity for Transfer

Unknown status·NNational University Hospital, Singapore··NCT04802278·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 54 trial records for COVID-19 Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — COVID-19 Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for COVID-19 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: Moderna

COVID-19 Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2030

Trials by Indication[1]

COVID-1927 trials

Influenza8 trials

Immunogenicity2 trials

Rheumatic Disease2 trials

Inflammatory Bowel Disease2 trials

Pregnancy2 trials

Hypertension2 trials

Liver Transplant1 trial

Vaccine1 trial

Immune Response1 trial

Sickle Cell Disease1 trial

Long COVID-191 trial

Vaccine Response1 trial

Lung Cancer1 trial

Blood Cancer1 trial

Immunity1 trial

References

Drug Info

Quick Facts

Related News